Last reviewed · How we verify
SanOrg34006
SanOrg34006 is a small molecule that acts as a selective inhibitor of the sodium-activated potassium channel, Nav1.5.
SanOrg34006 is a small molecule that acts as a selective inhibitor of the sodium-activated potassium channel, Nav1.5. Used for Atrial fibrillation for stroke prevention.
At a glance
| Generic name | SanOrg34006 |
|---|---|
| Sponsor | Sanofi |
| Drug class | Nav1.5 channel inhibitor |
| Target | Nav1.5 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
By inhibiting Nav1.5, SanOrg34006 is expected to reduce the frequency of atrial fibrillation episodes. This is achieved by stabilizing the cardiac action potential and reducing the excitability of atrial myocytes.
Approved indications
- Atrial fibrillation for stroke prevention
Common side effects
- Nausea
- Headache
- Dizziness
Key clinical trials
- Bioequipotency Study of Idrabiotaparinux and Idraparinux in Patients With Deep Venous Thrombosis of the Lower Limbs (PHASE3)
- Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach (PHASE3)
- Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation (PHASE3)
- SR34006 Compared to Placebo in Patients Who Have Completed 6 Months of Treatment for Symptomatic Pulmonary Embolism or Deep Vein Thrombosis (PHASE3)
- Safety and Efficacy Trial Evaluating the Use of SR34006 in the Treatment of Deep Vein Thrombosis (DVT) (PHASE3)
- Evaluating the Use of SR34006 Compared to Warfarin or Acenocoumarol in Patients With Atrial Fibrillation (AMADEUS) (PHASE3)
- SR34006 Compared to Vitamin K Antagonist (VKA) in the Treatment of Pulmonary Embolism (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SanOrg34006 CI brief — competitive landscape report
- SanOrg34006 updates RSS · CI watch RSS
- Sanofi portfolio CI